Lemtrada

Type: Product
Name: Lemtrada
First reported Sep 13 2014 - Updated Sep 13 2014 - 1 reports

The regulators got it wrong and throw drug away

J Pakpoor et al. Is there an increased cancer risk in people with relapsing multiple sclerosis taking cladribine? MS J Suppl The FDA/EMA saw a few cancers in the Movecro (oral cladribine) trial called CLARITY led by ProfG and wanted further trials ... [Published Multiple Sclerosis Research - Sep 13 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 2 reports

Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into ... [Published Zacks.com - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Pair of Multiple Sclerosis Drugs Produces Positive Long-Term Results

Krystle VermesPublished Online: Friday, September 12, 2014Follow Pharmacy_Times:At the Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis ... [Published Pharmacy Times - Sep 12 2014]
First reported Sep 10 2014 - Updated Sep 11 2014 - 11 reports

Sanofi Posts Promising Trial Results for MS Drug

Sanofi and its subsidiary Genzyme announced positive interim results from the second year of the extension study of Lemtrada (alemtuzumab) for multiple sclerosis.In this analysis, relapse rates and sustained accumulation of disability remained low among ... [Published Drug Discovery and Development - Sep 11 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

European Markets Tipped To Open Higher

The European markets are poised for a higher open on Thursday, ahead of the weekly jobless claims from the U.S. The DAX futures are rising 21.50 points, the CAC 40 futures are up 10 points and the FTSE 100 futures are gaining 15 points. The Swiss Market ... [Published RTTNews.com - Sep 11 2014]
First reported Sep 08 2014 - Updated Sep 09 2014 - 2 reports

Genzyme to Feature Multiple Sclerosis Pipeline and Present New Data on Aubagio and Lemtrada at ECTRIMS

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that its multiple sclerosis pipeline, which includes a new generation of investigational treatments in early development, will be featured during the 30thIn addition to its marketed ... [Published Wall Street Select - Sep 08 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Genzyme continues MS drug rollout across EU

Genzyme's plans to grow its multiple sclerosis business in Europe continued with the launch of two new treatments in the Republic of Ireland.The company, which serves as the biotech arm of French pharma firm Sanofi, today launched the injectable Lemtrada ... [Published PMLive - Sep 02 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

3 Reasons Sanofi's Stock Could Rise

After a rocky second quarter, biopharma stocks have rallied in a big way heading toward the end of the year. Gilead Sciences, for example, has shot up 41.5% year to date, with most of this upward movement coming in recent weeks. Sanofi's anemic gains, ... [Published Motley Fool - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Regulatory CD8 positive T cells controlling autoimmunity

Ping Y, Bamford R, Waldmann TA. IL-15-dependent CD8+ CD122+ T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4+ T cells. Eur J Immunol. 2014 doi: 10.1002/eji.201444675. [Epub ahead of print]Interleukin-15 ... [Published Multiple Sclerosis Research - Aug 27 2014]
First reported Aug 24 2014 - Updated Aug 24 2014 - 1 reports

Politics: drug pricing

Do Pharma CEOs' deserve their large bonuses? #MSBlog #MSResearch "Do MS DMTs justify their current premium? A large number of MS drugs are repurposed and hence their risk of failure has been low. Despite this the costs remain high.""Re-purposed licensed ... [Published Multiple Sclerosis Research - Aug 24 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

FDA Red Tape Blocks Effective Treatments

A dozen sunscreens sold abroad are more effective than those available here, but U.S. regulators have yet to OK them. A promising new MS drug, Lemtrada, has been in use for years in Europe yet American officials have rejected it. And it can take 15 years ... [Published NewsMax.com - Aug 21 2014]
First reported May 30 2014 - Updated May 31 2014 - 4 reports

US FDA accepts Genzyme's Lemtrada resubmission for review

The US Food and Drug Administration (FDA) has accepted for review the Genzyme's resubmission of supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.  A ... [Published PharmaBiz - May 31 2014]

Quotes

"I'm confident in the U S approval and I'm confident in how the product will perform and be utilized" Genzyme's MS and neurology head Mike Panzara told the news service. "... The efficacy is just too good."
...Genzyme's president and chief executive officer David Meeker said: "It is encouraging to see the durable efficacy and manageable safety of Lemtrada maintained two years into the extension study." The companies received EU approval for the drug last year based on studies carried out among more than 1,700 patients
...Speaking in a nationally televised primetime speech on the eve of the 13th anniversary of the 9/11 attacks, Obama said, "This is a core principle of my presidency: if you threaten America, you will find no safe haven."
"These extension study results provide further evidence of the prolonged efficacy of Lemtrada on both relapses and disability" said Dr. Alasdair Coles, senior lecturer at the Department of Clinical Neurosciences at the University of Cambridge, according to a Sanofi statement...

More Content

All (103) | News (35) | Reports (0) | Blogs (51) | Audio/Video (0) | Fact Sheets (0) | Press Releases (16)
sort by: Date | Relevance
The regulators got it wrong and throw drug away [Published Multiple Sclerosis Research - Sep 13 2014]
Sanofi Reports Data on Multiple Sclerosis Drug ... [Published Zacks.com - Sep 12 2014]
Pair of Multiple Sclerosis Drugs Produces Posit... [Published Pharmacy Times - Sep 12 2014]
At four years, treatment effect maintained in m... [Published MS News - Sep 12 2014]
Sanofi Posts Promising Trial Results for MS Drug [Published Drug Discovery and Development - Sep 11 2014]
Sanofi Releases Positive Data For New MS Drug [Published Bidness Etc - Sep 11 2014]
Sanofi keeps the faith in MS and eyes a new daw... [Published FierceBiotech - Sep 11 2014]
Sanofi and Genzyme report positive new data fro... [Published Zenopa - Sep 11 2014]
European Markets Tipped To Open Higher [Published RTTNews.com - Sep 11 2014]
SANOFI : Study Shows Positive Results from Lemt... [Published 4 Traders - Sep 11 2014]
Sanofi says MS drug Lemtrada shows sustained ef... [Published Reuters UK - Sep 11 2014]
At Four Years, Treatment Effect Maintained in M... [Published Fort Mills Times - Sep 11 2014]
At Four Years, Treatment Effect Maintained in M... [Published Digital Journal - Sep 11 2014]
Sanofi aims to grow Genzyme unit with new drugs... [Published Reuters - Sep 11 2014]
At Four Years, Treatment Effect Maintained in M... [Published Genzyme Press Release - Sep 11 2014]
At Four Years, Treatment Effect Maintained in M... [Published Sanofi.com - Last press releases - Sep 11 2014]
At Four Years, Treatment Effect Maintained in M... [Published Business Wire Health News - Sep 11 2014]
Genzyme to Feature Multiple Sclerosis Pipeline ... [Published Pharmacy Choice - Sep 10 2014]
For multiple sclerosis sufferers, an anxious hope [Published Boston Globe - Sep 09 2014]
Genzyme to Feature Multiple Sclerosis Pipeline ... [Published Wall Street Select - Sep 08 2014]
Genzyme to Feature Multiple Sclerosis Pipeline ... [Published Genzyme Press Release - Sep 08 2014]
Genzyme to Feature Multiple Sclerosis Pipeline ... [Published Business Wire Health News - Sep 08 2014]
Genzyme continues MS drug rollout across EU [Published PMLive - Sep 02 2014]
Preliminary alemtuzumab survey results [Published Multiple Sclerosis Research - Aug 31 2014]
OpportunityAnalyzer: Graft-Versus-Host Disease ... [Published MarketResearch.com - Aug 30 2014]
GVHD Industry (Life sciences) Insights & Analys... [Published MyNewsDesk - Aug 29 2014]
3 Reasons Sanofi's Stock Could Rise [Published Motley Fool - Aug 28 2014]
Regulatory CD8 positive T cells controlling aut... [Published Multiple Sclerosis Research - Aug 27 2014]
OpportunityAnalyzer: Graft-Versus-Host Disease ... [Published PredictWallStreet - Aug 25 2014]
OpportunityAnalyzer: Graft-Versus-Host Disease ... [Published Global Information Inc - Aug 25 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
The regulators got it wrong and throw drug away [Published Multiple Sclerosis Research - Sep 13 2014]
J Pakpoor et al. Is there an increased cancer risk in people with relapsing multiple sclerosis taking cladribine? MS J Suppl The FDA/EMA saw a few cancers in the Movecro (oral cladribine) trial called CLARITY led by ProfG and wanted further trials ...
At four years, treatment effect maintained in m... [Published MS News - Sep 12 2014]
Sanofi and its subsidiary Genzyme has announced positive interim results from the second year of the extension study of Lemtrada(TM) (alemtuzumab) for multiple sclerosis. ...
At Four Years, Treatment Effect Maintained in M... [Published Business Wire Health News - Sep 11 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today positive interim results from the second year of the extension study of Lemtrada™ (alemtuzumab) for multiple sclerosis. In this analysis, relapse ...
Genzyme to Feature Multiple Sclerosis Pipeline ... [Published Business Wire Health News - Sep 08 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that its multiple sclerosis pipeline, which includes a new generation of investigational treatments in early development, will be featured during ...
Preliminary alemtuzumab survey results [Published Multiple Sclerosis Research - Aug 31 2014]
When the results of a survey change the way you see the world; having progressive MS is like having a different disease. #MSBlog #MSResearch "Last week I did a ClinicSpeak post on ' when to say no to alemtuzumab ' and linked it to a survey. The preliminary ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
At Four Years, Treatment Effect Maintained in M... [Published Genzyme Press Release - Sep 11 2014]
At Four Years, Treatment Effect Maintained in M... [Published Sanofi.com - Last press releases - Sep 11 2014]
Genzyme to Feature Multiple Sclerosis Pipeline ... [Published Genzyme Press Release - Sep 08 2014]
Genzyme’s Lemtrada Approved in Argentina for Tr... [Published Genzyme Press Release - Jun 30 2014]
Genzyme’s Lemtrada Resubmission Accepted for Re... [Published Genzyme Press Release - May 30 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.